TX000045- Dose A + TX000045- Dose B + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Hypertension
Conditions
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Trial Timeline
Sep 4, 2024 → Nov 20, 2026
NCT ID
NCT06616974About TX000045- Dose A + TX000045- Dose B + Placebo
TX000045- Dose A + TX000045- Dose B + Placebo is a phase 2 stage product being developed by Tectonic Therapeutic for Pulmonary Hypertension. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06616974. Target conditions include Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06616974 | Phase 2 | Recruiting |
Competing Products
20 competing products in Pulmonary Hypertension